Clinical Trial Demonstrates Procedural Efficiencies, Safety, Effectiveness and Non-Inferiority of DiamondTemp System DUBLIN, Jan. 29, 2021 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of the DiamondTemp™ Ablation (DTA) system which treats patients with recurrent, symptomatic paroxysmal atrial […]
Tag: Medtronic
Sean Salmon Named EVP & President Cardiovascular Portfolio; Continues as EVP & President Diabetes Operating Unit
DUBLIN, Dec. 14, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT) announced today that Sean Salmon, Executive Vice President and President, Diabetes Operating Unit has been named Executive Vice President and President, Cardiovascular Portfolio effective January 1. Salmon will also continue to lead the Diabetes Operating Unit and continue to serve on the company’s Executive Committee. He […]
Medtronic Reports Second Quarter Fiscal 2021 Financial Results
– Q2 Revenue of $7.6 Billion Decreased 0.8% Reported and 1.5% Organic – Q2 GAAP Diluted EPS of $0.36; Q2 Non-GAAP Diluted EPS of $1.02 DUBLIN, Nov. 24, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2021, which ended October 30, 2020. The company reported second quarter worldwide revenue of $7.647 billion, […]
The New England Journal of Medicine: Medtronic Cryoablation is a Superior Treatment Option for Symptomatic Paroxysmal Atrial Fibrillation Compared to Drug Therapy
Results from Three Studies Show Medtronic Cryoablation is Superior to Drug Therapy for First-Line Treatment DUBLIN, Nov. 16, 2020 /PRNewswire(opens new window)/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the primary results of the Medtronic-sponsored STOP AF First clinical trial have been published in the New England […]
Medtronic Venous Stent Receives U.S. FDA Approval to Treat Venous Outflow Obstruction
Abre™ Venous Self-Expanding Stent System Safe, Effective in Treating Challenging Deep Venous Lesions DUBLIN, Oct. 26, 2020 /PRNewswire(opens new window)/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for the Abre™ venous self-expanding stent system. This device is indicated for […]
Titan Medical Announces Achievement of $10 Million Technical Milestone Under Medtronic Development and License Agreement
TORONTO–(BUSINESS WIRE)–Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it has completed the first technical milestone under the development and license agreement with Medtronic plc (“Medtronic”) […]
Nine-Month Results from Medtronic IN.PACT BTK Study Presented in Late-Breaking Clinical Trial Sessions at TCT Connect Annual Meeting
Feasibility Study of Medtronic Drug-Coated Balloon Technology for Challenging Below-the-Knee Disease Shows Promise in Patients with Critical Limb Ischemia DUBLIN, Oct. 18, 2020 /PRNewswire/ — Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the first-ever results from the IN.PACT BTK Study, a feasibility study assessing the safety and effectiveness […]
Medtronic Launches Head-to-Head TAVR Study Comparing the Evolut™ TAVR Platform Against the Edwards SAPIEN Valve in Small Annulus Patients
Medtronic Also Begins Feasibility Study of Evolut TAVR System in Moderate and Asymptomatic Aortic Stenosis Patients DUBLIN, Oct. 14, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in structural heart therapies, today announced it will begin a randomized, head-to-head study comparing two transcatheter aortic valve replacement (TAVR) systems in patients with severe symptomatic aortic […]
Medtronic Announces Partnership with The Foundry to Develop Innovative Mitral Valve Repair Technology
Half Moon Medical’s Technology Now Ready for Evaluation in Early Feasibility Study DUBLIN, Oct. 14, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a partnership with The Foundry – a medical device company incubator – dating back to mid-2017 to invest in and create a company with the […]
Medtronic Resolute Onyx™ Drug Eluting Stent (DES) First to Receive One-Month DAPT Labeling in the U.S. with Expanded Indication for High Bleeding Risk Patients
DUBLIN, Oct. 1, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for new one-month of dual-antiplatelet therapy (DAPT) labeling with an expanded indication for high bleeding risk (HBR) patients implanted with the Resolute Onyx™ DES. The Resolute Onyx DES […]



